The study compared the effectiveness of adding the cannabis-based drug Sativex to temozolomide, for patients with a newly recurrent glioblastoma. The researchers observed better one-year survival rates in the group receiving Sativex.
This was a small study published in the British Journal of Cancer (BJC) covering a new phase 1b trial using Sativex – also known as nabiximols – a botanical formulation containing cannabinoids THC and CBD, alongside other components. These results will hopefully help fund a larger randomized trial in the near futire.
Cannabis Health UK has a detailed post about it here.